High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer. An ongoing phase II multicenter Finnish-Latvian cooperative study. 1990

T Hietanen, and D Baltina, and R Johansson, and S Numminen, and T Hakala, and L Helle, and R Valavaara
Tampere University Central Hospital, Dept. of Radiotherapy, Finland.

The efficacy of high dose toremifene (240 mg daily) in postmenopausal women with advanced breast cancer is investigated in this ongoing study. At present, 38 patients are fully evaluable. Ten patients have CR (26%), 16 PR (42%) (objective response rate 68%), 8 NC (21%), and 4 PD (11%). Most objective responses are in soft tissue tumors (14/17, 82%). The response rate is equally high in patients with positive or unknown estrogen receptor (ER) status. Median duration of responses and survival are not yet evaluable. Of 48 patients evaluable for side-effects, 22 (46%) experienced some kind of toxicity, which was mild in 64% of cases, moderate in 29%, and mostly of estrogenic type. The study will continue to confirm the results thus far obtained.

UI MeSH Term Description Entries
D007844 Latvia A country located in Eastern Europe, bordering the Baltic Sea, between Estonia and Lithuania. The capital is Riga. Republic of Latvia
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004965 Estrogen Antagonists Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. Estradiol Antagonists,Antagonists, Estradiol,Antagonists, Estrogen
D005260 Female Females
D005387 Finland A country in northern Europe, bordering the Baltic Sea, Gulf of Bothnia, and Gulf of Finland, between Sweden and Russia. The capital is Helsinki. Aland Islands,Ă…land Islands
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

T Hietanen, and D Baltina, and R Johansson, and S Numminen, and T Hakala, and L Helle, and R Valavaara
January 2012, Oncology letters,
T Hietanen, and D Baltina, and R Johansson, and S Numminen, and T Hakala, and L Helle, and R Valavaara
January 1991, Anticancer research,
T Hietanen, and D Baltina, and R Johansson, and S Numminen, and T Hakala, and L Helle, and R Valavaara
June 1990, Journal of steroid biochemistry,
T Hietanen, and D Baltina, and R Johansson, and S Numminen, and T Hakala, and L Helle, and R Valavaara
June 1990, Journal of steroid biochemistry,
T Hietanen, and D Baltina, and R Johansson, and S Numminen, and T Hakala, and L Helle, and R Valavaara
January 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
T Hietanen, and D Baltina, and R Johansson, and S Numminen, and T Hakala, and L Helle, and R Valavaara
January 2004, Breast cancer (Tokyo, Japan),
T Hietanen, and D Baltina, and R Johansson, and S Numminen, and T Hakala, and L Helle, and R Valavaara
January 1997, Cancer practice,
T Hietanen, and D Baltina, and R Johansson, and S Numminen, and T Hakala, and L Helle, and R Valavaara
July 2009, Cancer chemotherapy and pharmacology,
T Hietanen, and D Baltina, and R Johansson, and S Numminen, and T Hakala, and L Helle, and R Valavaara
April 1998, Japanese journal of clinical oncology,
T Hietanen, and D Baltina, and R Johansson, and S Numminen, and T Hakala, and L Helle, and R Valavaara
January 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
Copied contents to your clipboard!